A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

341

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Nab-Paclitaxel

Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.

DRUG

Gemcitabine

Gemcitabine will be administered as per the schedule specified in the respective arm.

DRUG

Oxaliplatin

Oxaliplatin will be administered as per the schedule specified in the respective arm.

DRUG

Leucovorin

Leucovorin will be administered as per the schedule specified in the respective arm.

DRUG

Fluorouracil

Fluorouracil will be administered as per the schedule specified in the respective arm.

DRUG

Atezolizumab

Atezolizumab will be administered as per the schedule specified in the respective arm.

DRUG

Cobimetinib

Cobimetinib will be administered as per the schedule specified in the respective arm.

DRUG

PEGPH20

PEGPH20 will be administered as per the schedule specified in the respective arm.

DRUG

BL-8040

BL-8040 will be administered as per the schedule specified in the respective arm.

DRUG

Selicrelumab

Selicrelumab will be administered as per the schedule specified in the respective arm.

DRUG

Bevacizumab

Bevacizumab will be administered as per the schedule specified in the respective arm.

DRUG

RO6874281

RO6874281 will be administered as per the schedule specified in the respective arm

DRUG

AB928

AB928 will be administered as per the schedule specified in the respective arm.

DRUG

Tiragolumab

Tiragolumab will be administered as per the schedule specified in the respective arm.

DRUG

Tocilizumab

Tocilizumab will be administered as per the schedule specified in the respective arm.

Trial Locations (23)

10032

Columbia University, New York

10065

Memorial Sloan Kettering Cancer Center, New York

15232

Hillman Cancer Center, Pittsburgh

20007

Lombardi Cancer Center, Georgetown University, Washington D.C.

28007

Hosp. G. U Gregorio Marañón, Madrid

28037

Hospital Universitario Ramon y Cajal, Madrid

31008

Clínica Universidad de Navarra, Pamplona

45122

Universitätsklinikum Essen, Essen

53226

Medical College of Wisconsin, Milwaukee

60637

Uni of Chicago Medical Center, Chicago

91010

City of Hope Comprehensive Cancer Center, Duarte

94158

Helen Diller Fam Comp Can Ctr, San Francisco

97239

Oregon Health and Science University, Portland

06510

Smilow Cancer Hospital at Yale New Haven, New Haven

02215

Dana-Farber Cancer Institute, Boston

07962

MorristownMedicalCenter, Morristown

277-8577

National Cancer Center Hospital East, Chiba

241-8515

Kanagawa Cancer Center, Kanagawa

104-0045

National Cancer Center Hospital, Tokyo

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08035

Hospital Universitario Vall d Hebron, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03193190 - A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | Biotech Hunter | Biotech Hunter